CD4 and neoplasm: However, in a murine colorectal model, targeting galectin-1 did not lower the frequency of CD4+CD25+ Tregs in the tumor, spleen as well as tumor-draining lymph nodes, whereas the proportion and immunosuppressive properties of CD8+CD122+PD-1+ Tregs were reduced [116].